Ozempic lawsuit: 2 billion dollars and growing.
-
Key Takeaways
Litigation status: Lawsuits involving Ozempic and other GLP-1 drugs have been grouped together in two separate multidistrict litigations (MDL), helping to expedite the legal process. One focuses on gastroparesis, with the other focusing on vision loss.
Number of lawsuits: 3,546 as of April 2026.
Injuries claimed: Severe gastroparesis (stomach paralysis), ileus (impaired bowel function), intestinal obstruction and permanent vision loss from non-arteritic anterior ischemic optic neuropathy (NAION).
Label status: In January 2025, the Ozempic label was updated to state that it is “not recommended in patients with severe gastroparesis,” but does not indicate that the drug itself may cause the condition. In September 2023, the U.S. Food & Drug Administration (FDA) added ileus warnings to Ozempic.
Settlements: No global settlements have been announced as of April 2026.
